BLSM - BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti- Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S- Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
BLSM - BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti- Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S- Positive NSCLC at IASLC 2026 World Conference on Lung Cancer